Estimating risk of clinically evident neuropathy in Type 2 diabetes: a UKPDS risk equation

Estimating risk of clinically evident neuropathy in Type 2 diabetes: a UKPDS risk equation

Opis bibliograficzny
Główni autorzy:	Coleman, R, Stevens, R, Holman, R
Format:	Conference item
Wydane:	Blackwell 2006

Podobne zapisy

Incident nephropathy in type 2 diabetes: a UKPDS Risk Equation
od: Coleman, R, i wsp.
Wydane: (2005)

Estimating cardiovascular disease risk for individuals with Type 2 diabetes: the new UKPDS Risk Engine
od: Coleman, R, i wsp.
Wydane: (2007)

Framingham equations underestimate cardiovascular risk compared with the UKPDS risk engine in people with Type 2 diabetes
od: Price, H, i wsp.
Wydane: (2007)

Forecasting coronary case fatality in type 2 diabetes: a UKPDS Risk Engine equation
od: Stevens, R, i wsp.
Wydane: (2002)

Risk factors for neuropathy in UKPDS
od: Stratton, I, i wsp.
Wydane: (2004)

UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine.
od: Kothari, V, i wsp.
Wydane: (2002)

Evaluating SCORE and Framingham fatal coronary heart disease risk equations using UKPDS data
od: Coleman, R, i wsp.
Wydane: (2004)

Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90)
od: Leal, J, i wsp.
Wydane: (2021)

UKPDS58--modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes.
od: Stevens, R, i wsp.
Wydane: (2002)

Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66.
od: Stevens, R, i wsp.
Wydane: (2004)

Performance of the UKPDS Risk Engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort
od: Simmons, R, i wsp.
Wydane: (2008)

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).
od: Stevens, R, i wsp.
Wydane: (2001)

Estimating cardiovascular risk and all-cause mortality in individuals with type 2 diabetes using the UKPDS Outcomes Model
od: Coleman, RL, i wsp.
Wydane: (2019)

Plasma homocysteine, type 2 diabetes and risk of coronary heart disease in the UKPDS
od: Holman, R, i wsp.
Wydane: (2001)

Could non-HDL cholesterol replace total/HDL cholesterol ratio to estimate coronary heart disease risk in the UKPDS risk engine?
od: Stevens, R, i wsp.
Wydane: (2004)

Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes.
od: Coleman, R, i wsp.
Wydane: (2007)

Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in Type 2 diabetes
od: Coleman, R, i wsp.
Wydane: (2007)

Risk factors for incident albuminuria and renal dysfunction in the UKPDS
od: Adler, A, i wsp.
Wydane: (2000)

UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes.
od: Adler, A, i wsp.
Wydane: (2002)

A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).
od: Clarke, P, i wsp.
Wydane: (2004)

Hypoglycaemia in patients with Type 2 diabetes in the UKPDS
od: Cull, C, i wsp.
Wydane: (2001)

Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29.
od: Davis, T, i wsp.
Wydane: (1999)

Ethnicity and long-term vascular outcomes in Type 2 diabetes: a prospective observational study (UKPDS 83).
od: Davis, T, i wsp.
Wydane: (2014)

Ethnicity and long-term vascular outcomes in Type 2 diabetes: A prospective observational study (UKPDS 83)
od: Davis, T, i wsp.
Wydane: (2014)

Changing aspirin use in patients with Type 2 diabetes in the UKPDS.
od: Cull, C, i wsp.
Wydane: (2004)

Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52).
od: Kohner, E, i wsp.
Wydane: (2001)

Ethnic differences in diabetic nephropathy - The UKPDS
od: Stevens, R, i wsp.
Wydane: (1999)

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).
od: Adler, A, i wsp.
Wydane: (2003)

Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79.
od: Davis, T, i wsp.
Wydane: (2013)

Cardiovascular risk estimated by UKPDS risk engine algorithm in diabetes
od: Kavaric Nebojsa, i wsp.
Wydane: (2018-12-01)

Framingham risk equations underestimate coronary heart disease risk in diabetes.
od: Stevens, R, i wsp.
Wydane: (2005)

An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).
od: Gray, A, i wsp.
Wydane: (2001)

Cardiovascular Events in People with Type 2 Diabetes: Performance of Framingham, UKPDS, and ADVANCE Risk Equations
od: Elaheh Yaghoubvand, i wsp.
Wydane: (2021-11-01)

UKPDS: Plasma leptin, obesity and plasma insulin in type 2 diabetic subjects
od: Widjaja, A, i wsp.
Wydane: (1996)

Increased risk of incident heart failure and death is associated with insulin resistance in people with newly diagnosed type 2 diabetes: UKPDS 89
od: Wamil, M, i wsp.
Wydane: (2021)

Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).
od: Clarke, P, i wsp.
Wydane: (2002)

Inaugural Conference: UKPDS Legacy and Precision Therapy for Type 2 Diabetes Mellitus
od: Rury Holman
Wydane: (2022-09-01)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
od: Turner, R, i wsp.
Wydane: (1999)

Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.
od: Matthews, DR, i wsp.
Wydane: (2004)

The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84).
od: Alva, M, i wsp.
Wydane: (2014)